Alnylam Pharmaceuticals Inc (ALNY)vsKailera Therapeutics, Inc. Common Stock (KLRA)
ALNY
Alnylam Pharmaceuticals Inc
$309.49
+2.76%
HEALTHCARE · Cap: $40.19B
KLRA
Kailera Therapeutics, Inc. Common Stock
$25.15
+0.60%
HEALTHCARE · Cap: $3.21B
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 8.4% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 59/100 (C).
ALNY
Buy59
out of 100
Grade: C
KLRA
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+84.7%
Fair Value
$2105.37
Current Price
$309.49
$1795.88 discount
Intrinsic value data unavailable for KLRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Growing faster than its price suggests
No standout strengths identified
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 51.9x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth, PEG Ratio. Revenue growth of 84.9% demonstrates continued momentum. PEG of 0.60 suggests the stock is reasonably priced for its growth.
Bull Case : KLRA
KLRA has a balanced fundamental profile.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 129.8x leaves little room for execution misses.
Bear Case : KLRA
The primary concerns for KLRA are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while KLRA is a value play — different risk/reward profiles.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (59/100 vs 22/100) and 84.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?